Sagimet Biosciences Inc. Board of Directors

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Mr. David A. Happel

Mr. David A. Happel

CEO, President & Director

Mr. Robert D'Urso

Mr. Robert D'Urso

Senior Vice President of New Products

Dr. Marie O'Farrell Ph.D.

Dr. Marie O'Farrell Ph.D.

Senior Vice President of Research & Development

Ms. Elizabeth Rozek Esq., J.D.

Ms. Elizabeth Rozek Esq., J.D.

General Counsel & Chief Compliance Officer

Dr. George W. Kemble Ph.D.

Dr. George W. Kemble Ph.D.

Executive Chairman of the Board

Mr. Thierry Chauche

Mr. Thierry Chauche

CFO & Principal Accounting Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.